metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREA...
Información de la revista
Vol. 29. Núm. S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(febrero 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(febrero 2024)
Acceso a texto completo
O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREATED FOR CHRONIC HEPATITIS C
Visitas
202
Marcus Vinícius de Acevedo Garcia Gomes1, Diogo Delgado Dotta1, Manuella Andrade Oliveira Sobral1, Carla Brígido Oliveira1, Isabela Bodaczny Taliberti1, Nadjanine Linhares Casimiro1, Glenda Alves Pereira Oliveira1, André Luís Ferreira Bruder1, Rosa Maria Nascimento Marcusso2, Betania da Silva Rocha1, Alexandre Trazzi1, PATRICIA ZITELLI1, Mário Guimarães Pessoa1
1 Gastroenterologia e Hepatologia Clínica, Hospital das Clinicas da Universidade de São Paulo da Faculdade de Medicina, São Paulo, Brasil
2 Bioestatística, Instituto de Infectologia Emílio Ribas, São Paulo, Brasil
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S1

Abstracts of the 2023 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Introduction: Patients with hepatitis C virus (HCV) with advanced fibrosis (F3/4) still presented a significant risk of developing hepatocellular carcinoma (HCC). There are models for HCC risk prediction, such as the HCC risk score developed by Iannou et al 2018. This study aimed to evaluate the prevalence and risk factors for hepatocellular carcinoma development in previously treated chronic HCV patients in an outpatient hepatology clinic at Hospital das Clinicas of University of São Paulo School of Medicine, Brazil.

Materials and Methods

This is a retrospective, observational and descriptive study in a series of 267 HCV patients. Review of patients’ medical records, applying HCC risk score immediately before and 6 months after SVR, excluding cases with insufficient data and HCC before treatment of HCV. Data collection is still in progress and final results will be available at presentation.

Results

The total sample of this study consists of 267 patients, of whom, 127 (47.6%) had F4 degree fibrosis. Overall, 17 patients developed HCC after a median follow up period of 3 years (6.4%). The mean of HCC risk score at 3 years calculated in pre treatment was 9.64% and post treatment was 4.32% (p=0.002). An accuracy of this score was slightly better in the pre treatment (AUROC=0.72) versus post treatment (AUROC=0.69) (Figure 1).

Conclusions

HCC risk score post treatment declines more than 50% compared to pre treatment of HCV, as expected in in patients with HCV cure.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos